NOVOZYMES NORTH AMERICA, INC.

Lobbying for NOVOZYMES NORTH AMERICA, INC.

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$140,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

North Carolina

Official filing document

Government bodies contacted 3

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 3

HR 2756
National Biotechnology Initiative Act of 2025
S 1387
National Biotechnology Initiative Act of 2025
HR 7366
Dietary Supplement Regulatory Uniformity Act

Lobbying activity 3

Agriculture

Issues related to sustainability, animal feed additives, renewable fuels, Generally Recognized as Safe (GRAS) Notification Program, biological products in agriculture, biotechnology and biological products, including the National Biotechnology Initiative Act of 2025 (H.R. 2756/S. 1387), and issues related to dietary supplements including H.R. 7366, the Dietary Supplement Regulatory Uniformity Act. Issues related to nutrition, FDA regulation of feed ingredients, and agricultural biotechnology.

Transportation

Issues pertaining to supply chain operations, movement of containers, SHIP IT Act (not yet introduced) related issues, and tariffs.

Environment/Superfund

Issues related to renewable fuels, E15, and biotechnology policy; no specific legislation.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.